Effects of tirofiban application time on middle-term clinical prognesis in patients with acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention
- VernacularTitle:急性ST段抬高心肌梗死直接PCI后替罗非班应用时间对中期临床预后的影响
- Author:
Jun GU
;
Wei HU
;
Hongbing XIAO
;
Xiaodi FENG
;
Xian JIN
;
Qiang YU
;
Guizhi YIN
;
Ping GUAN
;
Chengjun CHEN
;
Yueguang CHEN
;
Dadong ZHANG
- Publication Type:Journal Article
- Keywords:
Myocardial infarction;
Angioplasty,transluminal,percutaneous coronary;
Prognosis;
Tirofiban
- From:
Chinese Journal of Postgraduates of Medicine
2008;31(25):20-22
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of tirofiban application time on middle-term clinical prognosis in patients with acute ST segment elevation myocardial infarction (STEMI)treated by primary percutsneous coronary intervention (PCI). Methods The study of tirofiban was carried out in 50 patients with STEM[in cardiology department from January to December 2006. Twenty-nine patients were randomized to receive tirofiban after PCI for 24 - 36 hours(short time group, STG) and 21 patients for 48 - 72 hours (long time group,LTG). Clinical characteristics, angiography data, main adverse cardiovascular events (MACE) and coronary restenosis rate in 6-month follow-up of the two groups were. compared. Results Follow-up data showed that there was less intractable angina pectoris (14.3% vs 24.1%, P< 0.05) in LTG. But there was no significant difference in coronary restenosis rate between two groups. Conclusion Long time application of tirofiban following PCI in patients with STEMI could improve middle-term clinical prognosis by alleviating the incidence of intractable angina pectoris.
